Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors

NCT07127874 is registered in ClinicalTrials.gov with Pheon Therapeutics as lead sponsor.

NCT NCT07127874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07127874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Lead sponsor
Pheon Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 23, 2025
Completion date
May 31, 2028
Enrollment
165 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumors, colon cancer, lung cancer (nsclc), pancreatic cancer